BioAtla and GATC Health announced a $40 million special purpose vehicle to advance ozuriftamab vedotin (Oz-V), a CAB-ROR2 antibody-drug conjugate, into a registrational Phase 3 study for second-line plus oropharyngeal squamous cell carcinoma. The financing ties directly to the broader industry momentum: 2025 saw a surge of innovation in ADC designs, linkers and payloads, and multiple ADC programs progressed toward late-stage trials. The pairing of targeted capital and next-generation ADC architectures signals continued commercial and scientific focus on ADCs as a growing oncology modality.